| Literature DB >> 36204647 |
Xiaojiang Hu1,2, Hongqi Zhang1,2, Yanbin Li2,3, Guang Zhang1,2, Bo Tang1,2, Dongcheng Xu1,2, Mingxing Tang1,2, Chaofeng Guo1,2, Shaohua Liu1,2, Qile Gao1,2.
Abstract
Background: Differential diagnosis of spinal tuberculosis is important for the clinical management of patients, especially in populations with spinal bone destruction. There are few effective tools for preoperative differential diagnosis in these populations. The QuantiFERON-TB Gold In-Tube (QFT-GIT) test has good sensitivity and specificity for the diagnosis of tuberculosis, but its efficacy in preoperative diagnosis of spinal tuberculosis has rarely been investigated. Method: A total of 123 consecutive patients with suspected spinal tuberculosis hospitalized from March 20, 2020, to April 10, 2022, were included, and the QFT-GIT test was performed on each patient. We retrospectively collected clinical data from these patients. A receiver operating characteristic (ROC) curve was plotted with the TB Ag-Nil values. The cutoff point was calculated from the ROC curve of 61 patients in the study cohort, and the diagnostic validity of the cutoff point was verified in a new cohort of 62 patients. The correlations between TB Ag-Nil values and other clinical characteristics of the patients were analyzed.Entities:
Keywords: IGRAs. ROC curve; QFT-GIT; QuantiFERON-TB Gold In-Tube (QFT-GIT); T-SPOT.TB; disease duration; interferon-gamma release tests; spinal tuberculosis
Mesh:
Year: 2022 PMID: 36204647 PMCID: PMC9531113 DOI: 10.3389/fcimb.2022.983579
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
The clinical characteristics of recruited patients in two independent cohorts.
| Study cohort | P# | Validation cohort | P& | P$ | |||
|---|---|---|---|---|---|---|---|
| TB (28) | NTB (33) | TB (23) | NTB (39) | ||||
| Age, years | 53.93 ± 16.51 | 56.67 ± 13.41 | 0.478 | 53.57 ± 16.28 | 53.33 ± 13.58 | 0.952 | 0.454 |
| Sex, male, % | 16 (57) | 19 (58) | 0.973 | 14 (61) | 25 (64) | 0.799 | 0.531 |
| Course, days | 105 (45,180) | 60 (42,135) | 0.382 | 90 (30,210) | 60 (30,150) | 0.542 | 0.345 |
| BMI, kg/m^2 | 22.71 ± 3.06 | 22.72 ± 3.72 | 0.989 | 21.51 ± 4.26 | 22.06 ± 3.99 | 0.689 | 0.256 |
| Diabetes | 1 | 4 | 0.363 | 0 | 5 | 0.148 | 1.000 |
| Hypohepatia | 2 | 3 | 1.000 | 3 | 2 | 0.350 | 1,000 |
| Renal Insufficiency | 0 | 1 | 1.000 | 0 | 1 | 1.000 | 1.000 |
| Cancer | 0 | 3 | 0.243 | 0 | 10 | 0.010 | 0.075 |
| pulmonary tuberculosis | 9 | 0 | 0.000 | 4 | 0 | 0.016 | 0.154 |
| WBC, *109/L | 6.07 ± 2.26 | 6.73 ± 2.32 | 0.263 | 6.14 ± 2.20 | 7.08 ± 3.36 | 0.239 | 0.525 |
| CRP, mg/L | 11.34 (4.20,31.96) | 17.95 (3.12,61.80) | 0.733 | 25.58 (10.63,77.11) | 13.83 (1.30,38.78) | 0.133 | 0.326 |
| ESR, mm/h | 55.00 (29.25,81.00) | 74.00 (33.00,112.50) | 0.173 | 74.00 (63.00,107.00) | 50.00 (35.00,104.00) | 0.244 | 0.542 |
| TB antigen positive, % | 5 (18) | 1 (3) | 0.085 | 8 (35) | 0 (0) | 0.000 | 0.592 |
| QFT-GIT positive, % | 27 (96) | 12 (36) | 0.000 | 20 (87) | 11 (28) | 0.000 | 0.119 |
TB, spinal tuberculosis; NTB, non-tuberculosis;
#Comparisons were conducted between TB and NTB in study cohort.
&Comparisons were conducted between TB and NTB in validation cohort.
$Comparisons were conducted between the study cohort and validation cohort.
Figure 1QFT-GIT diagnostic effectiveness. (A). ROC curve by final diagnosis and TB Ag-Nil values in all 123 patients, study cohort and validation cohort; (B, C, D). TB Ag-Nil values in the TB group than in patients in the NTB group, both in all patients, in the study cohort and in the validation. (**** means P ≤ 0.0001).
Diagnosis performance of the QFT-GIT and adjusted QFT-GIT.
| AUC (95%CI) | Sensitive (95%CI) | Specificity (95%CI) | PPV (95%CI) | NPV (95%CI) | PLR (95%CI) | NLR (95%CI) | Accuracy | |
|---|---|---|---|---|---|---|---|---|
| All patients | 0.866 | 92.16% | 68.06% | 67.14% | 92.45% | 2.885 | 0.115 (0.044-0.299) | 78.05% |
| Study cohort | 0.864 | 96.43% | 63.64% | 69.23% | 95.45% | 2.652 | 0.056 | 78.69% |
| Validation cohort | 0.860 | 86.96% | 71.79% | 64.52% | 90.32% | 3.083 | 0.182 | 77.42% |
| Validation cohort | 0.860 (0.764-0.955) | 73.91% (51.31%-88.92%) | 84.62% | 73.91% (51.31%-88.92%) | 84.62% (68.79%-93.59%) | 4.804 (2.213-10.428) | 0.308 | 80.65% |
TB, spinal tuberculosis; NTB, non-tuberculosis; AUC, the area under the curve; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; CI, confidence interval.
*adjusted cutoff point=1.58IU/mL
Figure 2Correlation analysis between QFT-GIT and other indication: The red dots represent TB patients and the blue dots represent NTB patients. (A, D) Correlation analysis between TB Ag-Nil and WBC in TB patients or NTB patients; (B, E) Correlation analysis between TB Ag-Nil and ESR in TB patients or NTB patients; (C, F) Correlation analysis between TB Ag-Nil and CRP in TB patients or NTB patients; (G, H) Correlation analysis between TB Ag-Nil and course in TB patients or NTB patients;.